Paul Finnegan

Dr. Finnegan is Chief Executive Officer of Angiocrine Bioscience. He has more than 20 years of life science management experience in the biotechnology, pharmaceutical, and healthcare industries – including extensive operational and strategic leadership roles in venture-backed start-ups and multi-billion dollar publically listed global companies, complemented by service on boards of both private and public biotechnology companies. Most recently, Dr. Finnegan has been advising boards and senior management of emerging biotechnology and pharmaceutical companies on strategic, commercial, business development, clinical, and regulatory matters, including companies focused on cellular immunotherapy (for cancer) and cellular regenerative therapies.

From 2012-2014, Dr. Finnegan served as Vice President and General Manager, Asia-Pacific for ViroPharma, Inc., which was acquired by Shire PLC for $4.2 billion. In this role, he initiated ViroPharma’s business in the Asia-Pacific region, and launched and developed Cinryze® and commercialized Plenadren®. Dr. Finnegan concurrently served as Director (Board) of Imprimis Pharmaceuticals (2012-2013) and on the Audit, Compensation, and Nomination & Governance Committees.

From 2008-2011, Dr. Finnegan was retained exclusively to manage start-ups wholly funded by Avalon Ventures, where he was CEO of Avelas BioSciences and InCode Biotherapeutics, participated as board observer for various Avalon portfolio companies, and provided commercial, clinical and regulatory due diligence for new Avalon Fund investments. From 2007-2008, Dr. Finnegan served as founding CEO of Cecoura Therapeutics, a start-up wholly owned by Paramount BioSciences.

From 2001-2007, Dr. Finnegan served as Vice President of Commercial Operations and Development, and then later as Vice President of Global Strategic Marketing for Alexion Pharmaceuticals, Inc. While at Alexion, Dr. Finnegan co-founded the paroxysmal nocturnal hemoglobinuria clinical program for eculizumab, built the first commercial organization, and initiated and led the global commercialization of Soliris® – the most successful ultra-orphan product launch in 2007.

From 1998-2000, Dr. Finnegan was Senior Director, Global Medical Marketing, APLAC Region for Searle, a division of Monsanto and then of Pharmacia Corp in 2000. While at Searle, Dr. Finnegan played key roles in his market region for the launch of Celebrex® – the most successful pharmaceutical product launch in 1999. Prior to Searle, Dr. Finnegan was a fellowship-trained interventional radiologist and an entrepreneur in the healthcare provider segment. Dr. Finnegan earned his M.D., C.M. from McGill University, Montreal, Canada, and his M.B.A. in Finance and Strategy from the University of Chicago, Booth Graduate School of Business and is a Fellow of the Royal College of Physicians, Canada (FRCPC) and a Member of the American Society of Hematology (ASH).